Censavudine

Drug Profile

Censavudine

Alternative Names: 4'-Ethynyl-d4T - Oncolys BioPharma; 4'-ethynylstavudine; BMS-986001; Ed4T; Festinavir; NRT inhibitor - Bristol-Myers Squibb; OBP-601

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kagoshima University; Yale University
  • Developer Bristol-Myers Squibb
  • Class Antivirals; Furans; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - HIV-1 infections

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 31 May 2016 Censavudine is available for licensing as of 30 Apr 2014. http://www.oncolys.com
  • 14 Jul 2014 Bristol-Myers Squibb terminates a phase II trial in HIV-1 infections (combination therapy, in treatment-naive patients) in Argentina, Australia, Canada, Chile, Colombia, France, Germany, Hungary, Mexico, Peru, Poland, South Africa, Spain and Thailand (NCT01489046)
  • 10 Feb 2012 No development reported - Preclinical for HIV-1 infections in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top